https://www.selleckchem.com/pr....oducts/Metformin-hyd
ion of bezafibrates appeared to induce the strongest beneficial effect in this cohort (Paris II 24 vs. 74%, = 0.004; Barcelona 50 vs. 84%, 0.046; ALP 1.67 × ULN and bilirubin ≤ 1 × ULN 33 vs. 86%, 0.001). Our large retrospective multicenter study confirms high response rates following UDCA first-line standard treatment in patients with PBC and highlights the need for close monitoring and early treatment modification in high-risk patients with an insufficient response to UDCA since early treatment modific
Like
Comment
Share
